We present the case of a patient with acromegaly who had pancytopenia with hypopituitarism secondary to the excision of a pituitary macroadenoma and radiation therapy. A 28-year-old man presented with pancytopenia and serum electrolyte abnormalities. He was diagnosed with acromegaly and underwent surgery and gamma-knife radiotherapy for a pituitary macroadenoma at the age of 22 years. A recent brain magnetic reso nance imaging showed an empty sella, and the basal hormonal profile demonstrated deficiencies of pituitary hormones except thyrotropin. As presenting pancytopenia, his bone marrow biopsy showed hypocellular marrow. The total number of hemocytes increased after hydrocortisone replacement. Hypopituitarism was a possible cause of pancytopenia, and glucocorticoids had crucial effects on converting pancytopenia to normal in this case. (Endocrinol Metab 27:308-313, 2012) 
INTRODUCTION
Acromegaly is not a common disease and its annual estimated incidence is 3-4 cases per 1 million people worldwide [1] . Hypopituitarism is reported to occur in over 50% of patients with acromegaly 5-10 years after radiation therapy [2] .
Aplastic anemia is a clinical condition that results from a marked diminution of marrow blood cell production. Its diagnosis is usually based on the presence of pancytopenia accompanied by hypocellular marrow without abnormal or malignant cells or fibrosis.
It is sometimes related to connective tissue disease, idiosyncratic responses to certain pharmaceuticals, exposure to toxic chemicals, and systemic diseases, such as infection [3] . While hormonal deficiency is rarely thought of a cause of pancytopenia with hypocellular bone marrow, the mechanisms of hormonal effects on hematopoiesis have not yet been fully understood and there have been only a few cases with bone marrow hypoplasia and pancytopenia which were related to hormone insufficiencies. We experienced a case of an acromegalic patient with pancytopenia who developed in hypopituitarism after surgical treatment and radiotherapy but recovered completely with hydrocortisone replacement therapy.
CASE REPORT
A 28-year-old man was referred from a private clinic with a history of mandibular hypertrophy and peripheral thickening in the hands and feet, 6 years ago. His insulin like growth factor 1 (IGF-1) level increased to 1,197.6 ng/mL (normal, 114-492). Oral glucose tolerance test results revealed that growth hormone (GH) levels were not suppressed (63 ng/mL), so the patient was diagnosed with acromegaly. Pituitary macroadenoma had been found on magnetic resonance imaging (MRI) (Fig. 1A) , and he underwent surgery through the transsphenoidal approach for pituitary macroadenoma removal the same year. One month after surgery, the IGF-1 level was 1,318.1 ng/mL, thyroid function tests were normal, and the prolactin level was 15.5 ng/mL (normal, 0-20). The adrenocorticotropic hormone (ACTH) level was 33.8 pg/mL (normal, 10-60) in the morning. MRI was performed 2 months after surgery and showed a remnant adenoma (Fig. 1B) . Then, he underwent gamma-knife radiosurgery (GKS). After GKS, he was transferred to the endocrinology depart- The patient visited the emergency department 6 years after radioment and still had a high level of IGF-1 (1,298.7 ng/mL). Thus, we prescribed bromocriptine 2.5 mg per day for 1 month, which was changed to Sandostatin LAR (Octreotide acetate, Novatis Pharm., Basel, Switzerland) 20 mg monthly. After 8 months, the IGF-1 levels were still high, so we increased the dose of Sandostatin LAR to 30 mg monthly after using 20 mg. The IGF-1 levels finally showed a http://www.enm-kes.org (Fig. 4) .
DISCUSSION
Pancytopenia rarely occurs in bone marrow failure syndrome secondary to hypopituitarism. There have been several reports of pancytopenia that are related to hormone deficiency. We reviewed nine cases by using Medline search ( Table 2) . Six of these cases were associated with Sheehan syndrome [4] [5] [6] [7] [8] [9] , one was associated with macroprolactinoma [10] , and one with hypothalamic glioma and one with suprasellar germinoma [11, 12] . To the best of our knowledge, this is the first case of pancytopenia secondary to hypopituitarism.
It is not clear which hormones are important to induce or improve pancytopenia in cases of pancytopenia due to hypopituitarism.
Most patients recover by simultaneous replacement of cortisol and thyroid hormone [4] [5] [6] [7] 9] . Lee [12] described a case of an 11-year-old girl who developed postablative hypothyroidism and prolonged pancytopenia after radiotherapy for a suprasellar germinoma while receiving cortisol replacement. Hence, the authors believed that hypothyroidism was a major contributing factor to pancytopenia in patients with panhypopituitarism. Conversely, Laway et al. [8] reported a patient with Sheehan's syndrome who had pancytopenia and hyponatremia. The patient was treated with hydrocortisone and showed a complete recovery from pancytopenia. They concluded that glucocorticoids play a crucial role in reversing pancytopenia in Sheehan's syndrome [8] . Badawi et al. [11] reported a young male patient with long-term panhypopituitarism and pancytopenia attributable to poor adherence to androgen replacement therapy, which resolved after institution of testosterone therapy. They emphasized the importance of testosterone in the treatment of hypopituitarism-induced pancytopenia.
Even though hormonal effects of hormone levels on myelopoie- [15, 16] . Steroid hormones directly stimulate erythropoiesis [13] . In addition, GH and IGF-1 are known to have a direct effect on erythroid and myeloid precursor progenitor cells [17, 18] .
Our patient showed mild pancytopenia for 3 years and pancytopenia worsen during two events of electrolyte imbalance. During each event, the patient had the similar symptoms, such as nausea, vomiting and diarrhea, and the symptoms improved with physiologic doses of hydrocortisone. Thus, he was diagnosed as having hypopituitarism with adrenal crises, which was probably caused by the stress of gastroenteritis. Uniquely, the patient showed insufficiencies of pituitary hormones except thyrotropin. Even testosterone level was low, though it had been low since he diagnosed acromegaly. We ruled out testosterone deficiency because testosterone levels had been low for a long time and there were no symptoms associated with testosterone deficiency. At first, we recommended testosterone replacement therapy, but he refused it. Moreover, after only administration of hydrocortisone, the patient showed a full recovery from pancytopenia. Therefore, this case supports the hypothesis that glucocorticoids are effective in treating pancytopenia induced by hypopituitarism.
In conclusion, hypopituitarism itself might be a possible cause of pancytopenia, although it rarely develops the aforementioned hematologic abnormalities due to an excess of GH in acromegaly. 
